AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01048359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
Study NCT01048359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention plus Booster
Description: A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
Study NCT01048359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: A brief drug use intervention based on motivational interviewing is provided to participants at baseline
Study NCT03939065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Augmented Pump Therapy
Description: Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
Study NCT03939065 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care with CGM
Description: Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
Study NCT02465814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
Study NCT02465814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670
Description: Placebo (12 weeks),Vilaprisan (12 weeks)
Study NCT02465814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670
Description: Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
Study NCT02465814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
Study NCT02465814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Study NCT02385214 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide Local Excision = 1cm Margin
Description: A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.
Study NCT02385214 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wide Local Excision = 2cm Margin
Description: A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.
Study NCT02719327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icosapent ethyl (IPE)
Description: Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
Study NCT02719327 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gel cap placebo
Description: Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
Study NCT03029702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin will be used for GDM treatment
Study NCT03029702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Glyburide will be used for GDM treatment
Study NCT03029702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be used for GDM treatment
Study NCT04282278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab/sintilimab+ Standard chemotherapy
Description: Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
Study NCT04282278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab/sintilimab+ apatinib（Intolerance to chemotherapy / refuse chemotherapy）
Description: Camrelizumab/sintilimab：200mg，iv，30min，d4，q3w，24 months Apatinib：250mg，d1，qd，po
Study NCT04282278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab/sintilimab+ apatinib+ Standard chemotherapy
Description: Camrelizumab/sintilimab：200mg，iv，30min，d7，q3w，24 months Apatinib：250mg，d1，qd，po Standard chemotherapy：Researcher chooses standard treatment by recommended guidelines，d 1-3
Study NCT03200158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endoscopy biopsy and blood
Description: Medical operation
Study NCT01479504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin and docetaxel
Description: neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
Study NCT01479504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin and docetaxel
Description: neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
Study NCT02465814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
Study NCT02353754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine injection
Description: 0.2 mg
Study NCT02353754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: 266 mg
Study NCT03851133 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
Study NCT03851133 — intervention group
Intervention type: OTHER
Intervention: Tumor Sample collection
Description: At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
Study NCT03851133 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
Study NCT01941914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium chloride
Study NCT02465814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulipristal
Description: Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
Study NCT03913286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortimo
Description: The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
Study NCT02098603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Testing & Intervention
Description: Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
Study NCT01428713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral tranexamic acid
Description: Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
Study NCT01428713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Contraceptive Pills
Description: Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
Study NCT02002858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Study NCT02002858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Study NCT02002858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression and Anxiety Smoking Cessation Treatment
Description: Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
Study NCT03335111 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Conditioning Equipment
Description: BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
Study NCT03335111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous blood collection
Description: Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
Study NCT03145077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI
Study NCT03145077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03335111 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intravenous blood collection
Description: Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
Study NCT02367989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0g barley β-glucan no fibre
Description: Food containing no barley β-glucan and no additional fibre
Study NCT02367989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2g barley β-glucan
Description: Food containing low amounts of barley β-glucan
Study NCT02367989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4g barley β-glucan
Description: Food containing medium amounts of barley β-glucan
Study NCT02367989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6g barley β-glucan
Description: Food containing high amounts of barley β-glucan
Study NCT02367989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0g barley β-glucan with fibre
Description: Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
Study NCT04213846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Mobile Alcohol Expectancy Intervention
Description: Participants randomized to the intervention condition will receive daily intervention messages two times a day for three weeks in the mobile app. The intervention uses participants' own daily responses to personalize messages, when appropriate, that challenges their personal expectations of alcohol's positive effects on mood, social facilitation, and tension reduction, as well as aggression and risk-taking. The intervention messages also focus on intentions to drink and pharmacologically-delayed negative effects. Intervention Messages in general will include feedback based on selected assessment items, weekly summaries generated from the daily assessments, general psycho-educational messages and videos about alcohol, and a toolbox with supplemental information (e.g., personal BAC calculators, resources).
Study NCT04622462 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of Care Histopathology
Description: Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
Study NCT04622462 — intervention group
Intervention type: PROCEDURE
Intervention: STRATICYTE Assessment
Description: Assessment for risk of progression to oral cancer
Study NCT03516149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling Exercise
Description: Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
Study NCT01939860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written and verbal patient education on hypertension and its treatment
Study NCT05516342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAD IT! Programming
Description: LEAD IT! is an intervention that enables persons with dementia to lead activities for their peers. The activities take place on tablets.
Study NCT03248570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
Study NCT03248570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
Study NCT01376544 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol designed to evaluate (SLE 5000 ventilator)
Description: Assist control ventilation and pressure support ventilation
Study NCT02443285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Cefotaxime 2 gram every12 hours for 5 days
Study NCT00347659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLVR System
Description: Treatment is administered in a single treatment session.
Study NCT01965080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: One tablet Exemestane 25 mg daily
Study NCT03037060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]-(+)-PHNO PET scan
Description: PET scan
Study NCT03037060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Self-Administration
Description: Session for assessing motivation for consuming alcohol.
Study NCT03037060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craving Task
Description: Cue exposure paradigm
Study NCT03037060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan scan to analyze the PET data will be administered.
Study NCT03037060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological Assessment
Description: Cognitive questionnaires administered over course of study.
Study NCT00354393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00354393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study NCT00354393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine ditartrate
Study NCT00354393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Study NCT00354393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Study NCT00354393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Therapy
Study NCT00354393 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00354393 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Study NCT04941417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Two to three cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor will be administered before surgery, followed by another one to two cycles of neoadjuvant chemotherapy in combination with PD-(L)1 inhibitor and PD-(L)1 inhibitor monotherapy for up to 1 year.
Study NCT03871933 — intervention group
Intervention type: OTHER
Intervention: Measurement of lung function, electrocardiography, echocardiography and autonomic function
Description: Measurement of lung function, electrocardiography, echocardiography and autonomic function
Study NCT03514368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients treated with immune checkpoint blockade
Description: Tumor biopsy specimens and blood samples will be collected at different time points:~* Baseline~* before the 3rd ICB administration (blood samples only)~* before the 5th ICB administration (blood samples only)~* at the time of treatment permanent discontinuation (blood samples only)~* at the time of progression (tumor biopsy specimens only)~* after the last dose of ICB treatment (blood samples only taken twice per year until study termination)
Study NCT01796665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%
Study NCT01796665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acanya Gel
Study NCT01796665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product
Study NCT02342912 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Media Treatments
Description: Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
Study NCT04492722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5718
Description: Participants will receive once daily oral dose of AZD5718 as per the arms they are randomised, and will continue until Week 20.
Study NCT04492722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.
Study NCT04492722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10 mg
Description: Participants will receive once daily oral dose of 10 mg dapagliflozin for 8 weeks as an add-on therapy.
Study NCT02443285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: Ceftriaxone 2 gm every 24 hours for 5 days
Study NCT02026362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT:Multiple Antigens Specific Cellular Therapy
Description: autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
Study NCT02026362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
Study NCT02026362 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
Study NCT04437277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hepatitis C, serology
Description: Inclusion of patients in conventional hospitalization at Saint Joseph Hospital. Each consenting patient benefits from a screening HCV serology carried out during a biological sample indicated by his state of health. In the case of positive HCV serology, an additional sample will be taken in search of viral replication. All detectable HCV PCR patients will be admitted to hepatology consultation for assessment of liver status including non-invasive methods and possible treatment according to the conditions of the Marketing Authorization and recommendations for routine clinical practice. Data on management (treatment or non-treatment and treatment outcome: prolonged virological response 12 weeks after completion of treatment) will be collected.
Study NCT01681862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Health Record
Description: Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan.